

2026 Independent Medical Education Call for Grants

Issue Date: July 22, 2026

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 4 weeks to complete a full grant proposal through funding.gene.com . When submitting the application, please be sure to: • Select the Therapeutic Area (Neuroscience), and Disease State (Parkinson's Disease) • Include “ CGN July 2026 [Insert Program Title]” in the program title of the grant	August 19, 2026
Step 2	Grant decisions will be made by Genentech and decision notifications will be issued to the accredited educational provider through gFRS.	By September 1, 2026

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available CGN Focus Area:

Focus	Opportunity
Therapeutic Area: Neuroscience Disease Areas: Parkinson's Disease Primary Learning Audiences: Community primary care physicians, advanced practice providers, sleep medicine specialists Support Available: Up to \$150,000	As understanding of the underlying biology of Parkinson's disease advances, new diagnostic and therapeutic approaches are emerging that could potentially help identify and manage the disease in its prodromal and early phase. Research shows significant knowledge gaps regarding early Parkinson's disease presentations can lead to diagnostic delays. Recognizing early signs of Parkinson's disease prior to the onset of classic motor symptoms is essential for identification and management of the disease. This prodromal phase can span 5 to 20 years, so effective identification of early symptoms, which can include sleep disturbance, hyposmia, and constipation among the constellation of initial symptoms, is critical to catching the disease early, pursuing further clinical work up, and preparing for potential future therapies that target underlying biology to slow disease progression. 1,2 Genentech seeks to educate community PCPs, APPs, and sleep medicine specialists in the early identification of prodromal Parkinson's disease symptoms and appropriate next steps for associated testing. References: 1. Khan, A. Z., Lavu, D., & Neal, R. D. (2023). Parkinson's disease: a scoping review of the quantitative and qualitative evidence of its diagnostic accuracy in primary care. <i>British Journal of General Practice</i>, 74(740), e227-e232. https://doi.org/10.3399/bjgp.2023.0409 2. Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., Lang, E. A., Liepelt-Scarfone, I., Litvan, I., Marek, K., Obeso, J., Oertel, W., Olanow, C. W., Poewe, W., Stern, M., & Deuschl, G. (2015). MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i>, 30(12), 1600-1611. https://doi.org/10.1002/mds.26431